Group 1 - A new company, China Duty Free (Hohhot) Airport Commercial Management Co., Ltd., has been established with a registered capital of 20 million RMB [1] - The legal representative of the new company is Qi Shi [1] - The business scope includes comprehensive commercial management services, air cargo packing services, and sales agency [1] Group 2 - The company is jointly owned by China Duty Free (Beijing) Trading Co., Ltd. and Inner Mongolia Airport Commercial Management Co., Ltd. [1]

Core Insights - The overall revenue and profit of the company are under pressure due to the continued downturn in the real estate industry, with significant divergence in performance across its core segments [1] - The new green building materials segment has shown resilience, achieving revenue growth and profit improvement, while the real estate development and operation segment has faced severe adjustments, negatively impacting overall performance [1] Financial Performance - In 2025, the company reported total revenue of 91.113 billion yuan, a year-on-year decrease of 17.7%, with main business revenue at 90.612 billion yuan, down 17.44% [1] - The total profit for the year was 0.32 billion yuan, a dramatic decline of 92.91% year-on-year, while the net profit was -1.507 billion yuan, remaining relatively stable compared to the previous year [1] - The net profit attributable to shareholders was -1.009 billion yuan, representing an 81.83% year-on-year increase in loss [1] Segment Performance - The new green building materials segment achieved main business revenue of 79.58 billion yuan, an increase of 1.68% year-on-year, and a profit of 0.218 billion yuan, up by 0.915 billion yuan year-on-year [1] - Cement and clinker sales reached 83.45 million tons, a slight decline of 1.13% year-on-year, with cement sales at 73.32 million tons, down 2.85% [2] - The concrete business saw sales of 15.688 million cubic meters, a year-on-year increase of 20.3%, despite a decrease in selling price [2] Real Estate Development - The real estate development and operation segment faced significant contraction, with main business revenue dropping to 11.498 billion yuan, a decrease of 64.88% year-on-year [2] - The segment reported a total profit of -0.186 billion yuan, a decline of 1.339 billion yuan year-on-year, indicating a shift from profit to loss [2] - Key operational metrics showed a reduction in transferred area to 531,800 square meters, down 51.77% year-on-year, and a total contract signing amount of 10.912 billion yuan, down 18.98% [3]

Core Viewpoint - Rongchang Biopharmaceuticals experienced a significant increase in stock price and trading volume, indicating strong market interest and investor confidence in the company [1][2]. Group 1: Financial Performance - For the year 2025, Rongchang Biopharmaceuticals achieved a revenue of 3.251 billion yuan, representing a year-on-year growth of 89.36% [2]. - The net profit attributable to shareholders for the same period was 710 million yuan, reflecting a substantial increase of 148.33% compared to the previous year [2]. Group 2: Stock and Financing Activity - On March 30, Rongchang Biopharmaceuticals saw a stock price increase of 5.52%, with a trading volume of 1.77 billion yuan [1]. - The company had a net financing purchase of 60.09 million yuan on the same day, with a total financing balance of 768 million yuan, which is 3.57% of its market capitalization [1]. - The financing balance is above the 70th percentile of the past year, indicating a high level of investor engagement [1]. Group 3: Shareholder Composition - As of December 31, 2025, the second-largest shareholder is Hong Kong Central Clearing Limited, holding 9.0675 million shares, an increase of 225,700 shares from the previous period [3]. - New institutional investors include Yongying Medical Innovation Mixed Fund, which holds 4.6739 million shares [3]. - Other notable changes include a decrease in holdings by Wan Jia You Xuan and an increase by Hui Tian Fu Innovation Medical Mixed Fund [3].

Core Viewpoint - BlackRock increased its stake in Li Ning Company Limited (02331) by purchasing 1,963,792 shares at a price of HKD 21.7599 per share, totaling approximately HKD 42.7319 million, resulting in a new holding of about 131 million shares, representing 5.05% of the company [1][2]. Group 1 - BlackRock's recent acquisition of shares indicates a strategic investment in Li Ning, reflecting confidence in the company's future performance [1][2]. - The total amount invested by BlackRock in this transaction is approximately HKD 42.7319 million [1][2]. - Following the purchase, BlackRock's total shareholding in Li Ning has reached approximately 131 million shares [1][2].

Core Viewpoint - The chairman and executive director of China Biologic Products Holdings, Xie Qirun, has increased his stake in the company by purchasing 1.748 million shares at a price of HKD 5.73 per share, totaling approximately HKD 10.016 million, resulting in a new holding of about 7.748 million shares, representing 0.04% of the company [1][2]. Summary by Category - **Share Purchase Details** - Xie Qirun acquired 1.748 million shares of China Biologic Products at HKD 5.73 each [1][2] - The total investment amounted to approximately HKD 10.016 million [1][2] - **Post-Purchase Holdings** - After the purchase, Xie Qirun's total shareholding increased to approximately 7.748 million shares [1][2] - The new shareholding percentage is 0.04% of the total shares [1][2]

Group 1 - BlackRock reduced its stake in Cheung Kong Holdings (00001) by 17,933,936 shares on March 24, with an average price of HKD 59.5998 per share, totaling approximately HKD 1.069 billion [1][2] - After the reduction, BlackRock's remaining shareholding is approximately 180 million shares, representing a stake of 4.69% [1][2]

Core Viewpoint - The company, Anhui Conch Cement Co., Ltd., is set to hold an annual performance briefing for the year 2025 on April 8, 2026, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on April 8, 2026, from 15:00 to 17:00 [5][6]. - The meeting will be conducted via video and online interaction, allowing for real-time communication with investors [3][6]. - Participants from the company will include the executive director, general manager, and relevant management personnel from the finance department and board secretary's office [4]. Group 2: Investor Participation - Investors can participate in the meeting by logging into the Shanghai Stock Exchange Roadshow Center online [5][6]. - A question collection period is open from March 31, 2026, to April 7, 2026, where investors can submit their inquiries [2][5]. - The company will address commonly asked questions during the briefing [2][7].

Core Viewpoint - The U.S. Department of the Treasury has issued a general license authorizing specific transactions related to negotiations and conditional contracts for the sale of Lukoil International GmbH, as well as related maintenance activities [1]. Group 1 - The general license allows for negotiations regarding the sale of Lukoil International GmbH [1]. - The license also covers the signing of conditional contracts related to the sale [1]. - Maintenance activities associated with the sale are included under the authorized transactions [1].

Group 1 - The core point of the article is that the U.S. has allowed Luke Oil International Limited to conduct certain transactions [1] Group 2 - The decision indicates a potential shift in U.S. policy regarding international oil companies [1] - This move may open up new opportunities for Luke Oil in the U.S. market [1] - The implications of this decision could affect the competitive landscape in the oil industry [1]

Core Viewpoint - China Eastern Airlines reported a revenue of 139.94 billion yuan for 2025, reflecting a year-on-year growth of 5.92%, while the net profit attributable to shareholders was -1.63 billion yuan, an increase of 61.36% compared to the previous year [1] Group 1: Financial Performance - The company's basic earnings per share for 2025 was -0.11 yuan, with a weighted average return on equity of -16.81% [1] - The price-to-earnings ratio (TTM) is approximately -48.40 times, the price-to-book ratio (LF) is about 2.29 times, and the price-to-sales ratio (TTM) is around 0.71 times [1] - In Q4 2025, the gross margin was -1.42%, up 1.50 percentage points year-on-year but down 15.16 percentage points quarter-on-quarter; the net margin was -12.58%, an increase of 3.04 percentage points year-on-year but a decrease of 22.32 percentage points quarter-on-quarter [1] Group 2: Expense Management - Total operating expenses for the year were 14.34 billion yuan, a decrease of 1.43 billion yuan compared to the previous year; the expense ratio was 10.25%, down 1.69 percentage points year-on-year [1] - Sales expenses increased by 12.17% year-on-year, while management expenses decreased by 3.92%, R&D expenses decreased by 18.95%, and financial expenses decreased by 32.14% [1] Group 3: Shareholder Information - As of the end of 2025, the total number of shareholders was 125,700, a decrease of 24,200 from the end of Q3, representing a decline of 16.15%; the average market value per shareholder increased from 617,100 yuan to 1,054,300 yuan, a growth of 70.85% [2] Group 4: Business Overview - China Eastern Airlines, established on April 14, 1995, and listed on November 5, 1997, is headquartered in Shanghai and primarily engages in passenger, cargo, mail, and luggage transportation, along with related services [2] - The main revenue sources include passenger service revenue (92.50%), cargo service revenue (3.86%), ticket refund fees (1.74%), other revenues (1.28%), and ground service revenue (0.62%) [2] - The company is classified under the transportation industry, specifically in the aviation sector, and is associated with concepts such as civil aviation, aviation transportation, and benefits from RMB appreciation [2]